Skip to main content

Advertisement

Table 1 M-protein and serum free light-chain levels during IL-1 inhibition

From: The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome

Patient Sex Treatment M-protein Serum free light-chains
number    subtype g/L kappa (mg/l) lambda (mg/l) Ratio κ / λ
1 M Anakinra IgMκ & IgMλ 10.1 14.4 46.8 0.31
None (Day 4 after anakinra withdrawal) 7.7 14.7 53.9 0.27
Canakinumab day 28 10.6 18.6 51.0 0.36
Relapse (post-canakinumab) 9.3    
2 F None (pre-anakinra) IgGκ 6.8 88.3 12.4 7.12
Anakinra 5 59.9 9.4 6.35
None (day 5 after anakinra withdrawal) 4.1 69 13.5 5.11
Canakinumab Day 28 4.3 59.1 11.6 5.09
Relapse (post-canakinumab) 3.7 78.4 12.2 6.43
3 M None (day 5 after anakinra withdrawal) IgMκ 2.7    
Canakinumab day 28 3.5 19.1 19.8 0.96
4 M Anakinra IgGκ 2.9    
None (day 5 after anakinra withdrawal) 2.8    
Canakinumab day 28 3.2 14 10.3 1.36
Relapse (post-canakinumab) 2.5    
5 M Anakinra IgMκ 4.4    
None (day 6 after anakinra withdrawal) 4.5 19.4 12.4 1.56
Canakinumab day 28 5    
Relapse (post-canakinumab)     
6 M Anakinra IgMκ 6.8 25.5 20.6 1.24
None (day 4 after anakinra withdrawal) 6.1 29.2 15.8 1.85
Canakinumab day 28 5.6 29.3 17.9 1.64
Relapse (post-canakinumab) 6.3    
7 F Anakinra IgGκ n.d.    
None (day 3 after anakinra withdrawal) n.d. 15.3 15.1 1.01
Canakinumab day 28 n.d.    
Relapse (post-canakinumab) n.d.    
8 M Anakinra IgGκ n.d. 17 13.5 1.26
None (day 5 after anakinra withdrawal) n.d. 26.9 18.7 1.44
Canakinumab day 14 p.n.q. 18.4 18.1 1.02
Canakinumab day 28 (relapse) p.n.q. 23.9 23.2 1.03
  1. Free light-chains in the serum were measured with the Freelight assay, reference values: serum free kappa chains (3.3−19.4 mg/l); serum free kappa chains (5.7−26.3 mg/l); ratio kappa/labda light-chains (0.26−1.65). Abnormal values are indicated in bold. n.d. not detectable; p.n.q. present but not quantifiable